clinical trial · NCT06486441
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Gilead Sciences·phase3·active not recruiting·n = 640
Endometrial CancerSacituzumab govitecan-hziyDoxorubicinPaclitaxel
brief summary
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
started
Aug 28, 2024
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
Jan 15, 2026
official title
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol